EIB Provides €20 Million in Financing to SamanTree Medical for Real-Time Microscopy for Surgical Procedures
27.1.2026 07:00:00 CET | Business Wire | Press Release
SamanTree Medical, a European leader in surgical imaging innovation, has secured €20 million in financing from the European Investment Bank (EIB). The operation is backed by InvestEU, the EU’s flagship program to mobilize over €372 billion in additional investment from 2021 to 2027.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126080876/en/
The European Investment Bank (EIB) provides €20 million in financing to SamanTree Medical, a leader in surgical imaging innovation. The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures, R&D and continued development and advancement of the company's Histolog® Scanner, the first and only medical imaging device featuring massively parallel confocal microscopy. Shown: Alessandro Izzo, EIB Director (left) and Olivier Delporte, CEO of SamanTree Medical (right).
The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures. Furthermore, the financing will support SamanTree Medical’s research, development and innovative activities, including continued development and advancement of its Histolog® Scanner
The EIB financing is provided through the Bank’s Venture Debt Instrument and is designed to support highly innovative companies undertaking research-intensive development activities.
“The support of the European Investment Bank represents an important milestone for SamanTree,” said Olivier Delporte, CEO of SamanTree Medical. “This financing allows us to accelerate development of the Histolog Scanner and expand our commercial presence across Europe and the United States. The rigorous due diligence process undertaken by the EIB reflects the importance of our innovative technology, our development plan and our long-term vision for advancing real-time, high-resolution imaging for excised tissue.”
“Our investment in SamanTree Medical reflects the EIB’s long-standing commitment to advancing medical innovation across Europe,” said EIB Director Alessandro Izzo. “By supporting med‑tech companies through venture debt, a tool that helps entrepreneurs accelerate growth and bring cutting-edge technologies to patients sooner, we make sure that key medical tech companies can grow and thrive in Europe. Supporting innovators like SamanTree Medical is central to our mission of driving positive impact for patients and healthcare systems.”
The advanced technique of the Histolog Scanner enables it to capture nearly 30,000 images simultaneously, rather than one at a time, producing high-resolution, histology-like images in approximately one minute without damaging the specimen. This allows surgeons and pathologists to image tissue within minutes and determine whether abnormal cellular microstructures remain at the surgical site, while patients remain on the operating table. Used in more than 6,000 patients to date, physicians using the Histolog Scanner have demonstrated compelling results across multiple tissue types. In breast-conserving surgery, the SHIELD study showed that when physicians used the Histolog images for assessment, reoperation rates were lowered from 30% to 10%, a 67% reduction.
Research has also shown that Histolog is similar1 when compared to intraoperative frozen-section analysis (the gold standard) for prostatectomies, while offering substantial time savings. Using Histolog for imaging and interpretation takes approximately 5-20 minutes, compared with 45-60 minutes for frozen section analysis.2 Using the Histolog images, physicians have also demonstrated a sensitivity ranging from 73% - 91% and a specificity ranging from 91% to 100%, when compared to conventional pathology.1,2,3 Additionally, studies have shown that intraoperative assessment allows surgeons to opt for more nerve-sparing surgeries, significantly reducing erectile dysfunction, a common side effect of a radical prostatectomy.4
Background
The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States.
Headquartered in Liège, Belgium, SamanTree Medical is a privately held company dedicated to improving oncologic surgery through innovative imaging solutions.
1https://pubmed.ncbi.nlm.nih.gov/39403832/
2https://pubmed.ncbi.nlm.nih.gov/36440864/
3IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical Prostatectomy - PubMed
4https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00091-9/fulltext
View source version on businesswire.com: https://www.businesswire.com/news/home/20260126080876/en/
Contacts
Media contact
SamanTree: Amy Cook | +1 925 222 5094 | amy.cook@samantree.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press Release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press Release
Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s global C-130H fleet from 10 aircraft to 20 and gives its Canadian division the scale to build
Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 18:16:00 CEST | Press Release
Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault will supply battery energy storage systems ("BESS"), grid-forming power conversion systems and AI infrastructure controlsoftware to support an initial deployment totaling 1.25 gigawatts ("GW") of integrated power infrastructure for hyperscaler AI data centers. The agreement establishes a repeatable AI power infrastructure platform that combines dispatchable power generation, intelligent battery energy storage, grid-forming inverter systems, advanced AI infrastructure controls software and turnkey EPC and plant integration into a single integrated solution designed specifically for hyperscaler AI data centers and high-performance computing campuses. The companies will jointly deploy fully integrated, off-grid power systems capable of bringing AI compute capacity online significantly fas
SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 10:52:00 CEST | Press Release
SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously communicated. No future exceptional cash proceeds will be used to fund the project. Since the signing of the IRIS² Concession Contract in
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press Release
2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026 Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment eff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom